Acadia Pharma (ACAD) Tops Q3 EPS by 9c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $27.74 +0.22%
Revenue Growth %: +19.1%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +19.1%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.53), $0.09 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.03 million.
GUIDANCE:
Acadia Pharma sees FY2017 revenue of $124-127 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
- RH shares jump after second quarter beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
